Table 3 Individual patient estimates of amikacin pharmacokinetic parameters during CVVHDF therapy assuming a two compartment model
ID | k (h-1) | V1 (l) | TBC (l h-1) | T1/2α (h) | T1/2β (h) | T1/2el (h) | Vss (l) |
|---|---|---|---|---|---|---|---|
P1B | 0.093 | 25.0 | 2.32 | 0.25 | 8.18 | 7.45 | 27.33 |
P2C | 0.131 | 21.95 | 2.88 | 0.035 | 7.61 | 5.29 | 31.5 |
P3C | 0.172 | 24.31 | 4.19 | 0.028 | 5.29 | 4.02 | 31.94 |